Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) 0 or 1.~* Histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease.~* Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).~* Obtained complete response or Good partial response after first line chemotherapy.~* Normal organ function required prior to study entry.~* Willingness to comply with treatment plans and other study procedures.~Exclusion Criteria:~* Uncontrolled central nervous system (CNS) involvement with disease~* Fertile women unwilling to use contraceptive techniques during treatment~* Females who are pregnant~* Organ dysfunction.~* Patients may not be receiving any other investigational agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Metastatic triple negative breast cancer (Type: EXPERIMENTAL): Abraxane,Cyclophosphamide,Carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).